Passage Bio to Present at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 - Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, has announced its participation at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The event is set to take place virtually on Monday, April 29, 2024, at 9:00 a.m. ET. Passage Bio’s CEO, William Chou, M.D. and the senior vice president of technical operations, Eden Fucci, will be representing the company and engaging in a virtual fireside chat during the summit.
Passage Bio, a leading genetic medicines company, is dedicated to developing transformative therapies for patients with severe neurodegenerative diseases. With an unwavering focus on innovative approaches and cutting-edge technologies, Passage Bio aims to provide effective treatments that can significantly improve the lives of those suffering from these debilitating conditions.
The 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, organized by Chardans, brings together industry leaders, experts, and innovators in the field of genetic medicines and cell therapy manufacturing. This platform offers a unique opportunity for collaboration, knowledge sharing, and networking within the industry, helping to accelerate breakthrough discoveries and advancements towards effective treatments for various genetic disorders.
During the virtual fireside chat, William Chou, M.D. the president and CEO of Passage Bio, will share insights into the company’s latest advancements in genetic medicines and provide updates on their clinical-stage programs. Chou’s vast expertise and leadership in the field make him a valuable asset to the summit, offering valuable perspectives on the challenges and opportunities in the development and manufacturing of genetic therapies.
Eden Fucci, the senior vice president of technical operations at Passage Bio, will also contribute to the fireside chat, providing detailed insights into the technical aspects of genetic medicine and cell therapy manufacturing. With her deep understanding of the intricate processes involved in developing these therapies, Fucci will shed light on Passage Bio’s approach to ensuring quality, safety, and scalability of their innovative treatments.
Passage Bio’s participation at the summit serves as a testament to the company’s commitment to advancing the field of genetic medicines and cell therapy manufacturing. By actively engaging with industry peers and sharing their experiences and expertise, Passage Bio continues to contribute to the growth and development of innovative therapies that hold the potential to revolutionize the treatment of neurodegenerative diseases.
In conclusion, Passage Bio’s presence at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit marks an important milestone in their journey to develop effective treatments for patients with neurodegenerative diseases. The virtual fireside chat featuring Passage Bio’s CEO, William Chou, M.D. and SVP of technical operations, Eden Fucci, promises to offer valuable insights into their groundbreaking work and the future of genetic medicine. This summit presents a unique opportunity for industry leaders, experts, and innovators to come together, collaborate, and pave the way for the advancement of genetic medicines and cell therapy manufacturing.
Comments